BioCentury | Dec 7, 2018
Financial News

Panacea backs Tactiva in $35M series A

...Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first...
...round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
...million in a 2016 seed round (see “Third Cell's the Charm” ). Tactiva Therapeutics Inc., Buffalo, N.Y. Mark Zipkin Tactiva Therapeutics Inc. Multiple...
BioCentury | Dec 3, 2018
Financial News

Panacea backs Tactiva in $35M series A

...Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Monday it raised $35 million in a tranched series...
...round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
...in 2019, including a multiple myeloma (MM) trial and a basket trial in solid tumors. Tactiva...
BioCentury | May 5, 2017
Emerging Company Profile

Third cell’s the charm

...persist long enough to generate sufficient numbers of memory CD8+ cells to eliminate the tumor. Tactiva...
...T cells are transduced with one TCR, and the HSCs with a second TCR that Tactiva...
...tumor antigen, in Phase I testing. Neither Adaptimmune nor Kite responded to requests for comment. Tactiva...
Items per page:
1 - 3 of 3
BioCentury | Dec 7, 2018
Financial News

Panacea backs Tactiva in $35M series A

...Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Dec. 3 it raised $18 million in the first...
...round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
...million in a 2016 seed round (see “Third Cell's the Charm” ). Tactiva Therapeutics Inc., Buffalo, N.Y. Mark Zipkin Tactiva Therapeutics Inc. Multiple...
BioCentury | Dec 3, 2018
Financial News

Panacea backs Tactiva in $35M series A

...Cancer immunotherapy company Tactiva Therapeutics Inc. (Buffalo, N.Y.) announced Monday it raised $35 million in a tranched series...
...round led by Chinese VC firm Panacea Ventures. VI Ventures and EFung Capital also participated. Tactiva...
...in 2019, including a multiple myeloma (MM) trial and a basket trial in solid tumors. Tactiva...
BioCentury | May 5, 2017
Emerging Company Profile

Third cell’s the charm

...persist long enough to generate sufficient numbers of memory CD8+ cells to eliminate the tumor. Tactiva...
...T cells are transduced with one TCR, and the HSCs with a second TCR that Tactiva...
...tumor antigen, in Phase I testing. Neither Adaptimmune nor Kite responded to requests for comment. Tactiva...
Items per page:
1 - 3 of 3